Hanna

Hana Pharm is a South Korean pharmaceutical company specializing in the development and commercialization of specialty drugs, with a particular focus on anesthetics and analgesics. The company is best known for its partnership with Paion AG to commercialize Byfavo (remimazolam), a novel ultra-short-acting sedative used in general anesthesia and procedural sedation. Beyond its core anesthesia portfolio, Hana Pharm maintains a diverse range of products targeting circulatory, digestive, and respiratory conditions. The company operates multiple manufacturing facilities in South Korea and is actively expanding its global footprint through licensing agreements and export initiatives.